Renal disease. II. The clinical impact of recombinant human erythropoietin.
The introduction of rHuEPO has certainly improved the general well-being of many patients with ESRD. Most nephrologists would agree that treatment with rHuEPO is an important aspect of the management of selected ESRD patients in the 1990s. Additional uses for rHuEPO are beginning to be defined, including perioperative associated anaemia, and in the anaemias associated with cancer chemotherapy or prematurity. The use of rHuEPO in preparation for elective surgery seems poised to be the most significant of these potential indications.
Muirhead
N
N
University of Western Ontario, London, Canada.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin